MedTrace Logo

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

NCT02227173 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-11-18

No results posted yet for this study

Summary

This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of montelukast, flurbiprofen, and digoxin.

Conditions

  • Drug-drug Interaction Study

Interventions

DRUG

BMS-986020

DRUG

Montelukast

DRUG

Flurbiprofen

DRUG

Digoxin

Sponsors & Collaborators

Principal Investigators

  • Emanuel DeNoia, MD · ICON Development Solutions

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02227173 on ClinicalTrials.gov